Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hansa Biopharma AB ( (SE:HNSA) ) has provided an announcement.
Hansa Biopharma announced a successful capital raise of approximately 232 MSEK/US $24.3M and restructured its debt with NovaQuest, which will support upcoming Phase 3 trial readouts. The company’s IDEFIRIX product sales increased by 76% compared to the previous year, highlighting strong market performance. Additionally, Hansa appointed Maria Törnsén as COO and President U.S., and Dr. Richard Philipson as Chief Medical Officer, strengthening its leadership team. The company remains on track with its clinical pipeline, including a pivotal Phase 3 trial in kidney transplantation and trials in Guillain Barré Syndrome and Duchenne Muscular Dystrophy.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company has developed a unique IgG antibody-cleaving enzyme therapy for desensitizing highly sensitized kidney transplant patients and is active in transplantation, autoimmune diseases, and gene therapy. Hansa operates from Lund, Sweden, with a presence in Europe and the U.S.
Average Trading Volume: 248,558
Current Market Cap: SEK2.21B
Find detailed analytics on HNSA stock on TipRanks’ Stock Analysis page.